Fact CheckerSign in

NCT01727284Enrolling by invitation

MR-Guided Cryoablation of Prostate Bed Recurrences

Technical Success, Safety, and Short and Long-term Efficacy for MR-Guided Cryoablation of Prostate Bed Recurrences

Source: ClinicalTrials.gov · Last updated 25 Sept 2026

Brief summary (registry, in English)

The purpose of this research is to see if MR-guided cryoablation can effectively treat prostate tumor recurrences.

Status (registry)
Enrolling by invitation
Study type
Interventional
Enrollment
200 (estimated)
First submitted
12 Nov 2012
Start date
Dec 2012
Primary completion date
Dec 2028
Lead sponsor
Mayo Clinic
NCT number
NCT01727284

What you commit to

  • Study type: Interventional
  • Planned participants: 200
  • From Dec 2012 to the primary completion date, Dec 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • N/A

Who the study is looking for

  • Patients with "biopsy proven" soft tissue tumor or MRI/PET imaging convincing of recurrences of prostate fossa
  • Surgery is not a desirable alternative therapy at the time of enrollment
  • Radiation therapy has failed or not indicated or can be safely postponed
  • Tumor size is \< 5 cm at its largest diameter
  • Tumor does not encompass the rectal wall or external urethral sphincter
  • Patient is able to undergo MRI

Age in the registry: 30 years to 100 years · Sex: Male · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Mayo Clinic in Rochester
Coordinator of this site? Confirm its status		RochesterUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.